CASSADER, Maurizio
 Distribuzione geografica
Continente #
NA - Nord America 16.186
EU - Europa 11.484
AS - Asia 7.279
SA - Sud America 472
OC - Oceania 179
AF - Africa 128
Continente sconosciuto - Info sul continente non disponibili 24
Totale 35.752
Nazione #
US - Stati Uniti d'America 15.458
CN - Cina 4.662
IT - Italia 1.832
IE - Irlanda 1.588
SE - Svezia 1.444
FR - Francia 1.038
DE - Germania 916
UA - Ucraina 894
FI - Finlandia 672
KR - Corea 639
GB - Regno Unito 624
JP - Giappone 518
AT - Austria 466
CA - Canada 415
PL - Polonia 405
DK - Danimarca 370
VN - Vietnam 320
BE - Belgio 297
IN - India 272
MX - Messico 270
ES - Italia 245
BR - Brasile 194
AU - Australia 153
RU - Federazione Russa 142
TW - Taiwan 135
TR - Turchia 121
HK - Hong Kong 118
SG - Singapore 102
NL - Olanda 101
GR - Grecia 97
IR - Iran 62
RO - Romania 61
CO - Colombia 59
PE - Perù 59
TH - Thailandia 59
CL - Cile 55
ID - Indonesia 53
PT - Portogallo 47
AR - Argentina 45
EC - Ecuador 45
PH - Filippine 41
CZ - Repubblica Ceca 40
CH - Svizzera 38
EG - Egitto 34
SI - Slovenia 31
IL - Israele 30
MY - Malesia 30
SN - Senegal 29
NO - Norvegia 25
EU - Europa 24
BY - Bielorussia 22
HU - Ungheria 21
SA - Arabia Saudita 21
NZ - Nuova Zelanda 20
ZA - Sudafrica 18
GT - Guatemala 14
PK - Pakistan 13
RS - Serbia 12
LU - Lussemburgo 11
VE - Venezuela 11
QA - Qatar 10
BG - Bulgaria 9
TN - Tunisia 9
MU - Mauritius 8
SK - Slovacchia (Repubblica Slovacca) 8
IQ - Iraq 7
LV - Lettonia 7
MM - Myanmar 7
MV - Maldive 7
AE - Emirati Arabi Uniti 6
GH - Ghana 6
KZ - Kazakistan 6
UZ - Uzbekistan 6
AN - Antille olandesi 5
AZ - Azerbaigian 5
BD - Bangladesh 5
CR - Costa Rica 5
CV - Capo Verde 5
HR - Croazia 5
LB - Libano 5
BO - Bolivia 4
DZ - Algeria 4
HN - Honduras 4
JO - Giordania 4
KE - Kenya 4
PA - Panama 4
IS - Islanda 3
JM - Giamaica 3
LK - Sri Lanka 3
MO - Macao, regione amministrativa speciale della Cina 3
NI - Nicaragua 3
PG - Papua Nuova Guinea 3
SV - El Salvador 3
AL - Albania 2
EE - Estonia 2
GU - Guam 2
IM - Isola di Man 2
KH - Cambogia 2
LT - Lituania 2
MA - Marocco 2
Totale 35.728
Città #
Beijing 1.952
Chandler 1.851
Dublin 1.574
Ann Arbor 1.238
Fairfield 828
Houston 781
Jacksonville 692
Villeurbanne 630
Ashburn 624
Wilmington 609
Princeton 579
Woodbridge 568
Redwood City 484
Medford 467
Nyköping 437
Vienna 436
Dearborn 412
Torino 372
Seattle 354
Warsaw 325
Shanghai 304
Cambridge 297
Pisa 294
Brussels 236
Dong Ket 223
Boston 213
Guangzhou 193
Nanjing 175
Hangzhou 172
Ottawa 160
Boardman 155
Fremont 124
Milan 111
Tokyo 108
Wuhan 100
Norwalk 95
Taipei 91
Chengdu 89
Pune 88
New York 83
Toronto 79
London 70
Chongqing 69
Hefei 69
Rome 65
Shenyang 60
Jinan 59
San Diego 58
Verona 58
Tianjin 57
Changsha 51
Phoenix 50
Kunming 49
Falls Church 47
Menlo Park 46
Washington 44
San Mateo 43
Seoul 43
Xian 43
Istanbul 42
Central District 41
Turin 40
Zhengzhou 40
Lima 38
Santiago 37
Changchun 35
Munich 33
Nanchang 33
Mexico City 32
Düsseldorf 31
Helsinki 31
Central 30
Fuzhou 30
Silver Spring 30
Duncan 29
Mexico 28
Mountain View 28
Saint-hubert 28
Lachine 27
Madrid 27
Athens 26
Berlin 26
Saint Petersburg 24
Los Angeles 23
Riverton 22
Singapore 21
Sydney 21
São Paulo 21
Bogotá 20
Montréal 20
Paris 20
Rochester 20
Trissino 20
Xiamen 20
Chicago 19
Jakarta 18
Osaka 18
Saint Louis 18
Barcelona 17
Brisbane 17
Totale 20.685
Nome #
Diabetic ketoacidosis with SGLT2 inhibitors 1.904
Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. 1.380
Bioactive Lipid Species and Metabolic Pathways in Progression and Resolution of Nonalcoholic Steatohepatitis 801
Fatty liver and chronic kidney disease: Novel mechanistic insights and therapeutic opportunities 784
Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance 743
Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial 712
Simple lifestyle recommendations and the outcomes of gestational diabetes. A 2×2 factorial randomized trial 641
Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. 614
Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: mechanisms and implications for metabolic disorders 535
Interactions among bone, liver, and adipose tissue predisposing to diabesity and fatty liver. 456
Angiotensin II Type 1 Receptor rs5186 Gene Variant Predicts Incident NAFLD and Associated Hypertension: Role of Dietary Fat-Induced Pro-Inflammatory Cell Activation 399
New Pharmacologic Agents That Target Inflammation and Fibrosis in Nonalcoholic Steatohepatitis-Related Kidney Disease 331
Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease 291
Emerging molecular targets for the treatment of nonalcoholic fatty liver disease 278
Specialized Proresolving Mediators: Enhancing Nonalcoholic Steatohepatitis and Fibrosis Resolution 248
Contributors to the obesity and hyperglycemia epidemics. A prospective study in a population-based cohort. 238
A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. 218
Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis 217
Dietary flavonoid intake and cardiovascular risk: a population-based cohort study 204
Predictive role of the Mediterranean diet on mortality in individuals at low cardiovascular risk: A 12-year follow-up population-based cohort study 190
Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis 183
Body fat and C-reactive protein levels in healthy non-obese men. 182
Changes in the gut microbiota composition during pregnancy in patients with gestational diabetes mellitus (GDM) 182
Contribution of visceral fat and hepatic fat to metabolic derangements and liver damage in NAFLD patients. 181
Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease 181
Apolipoprotein H is increased in type 2 diabetic patients with microalbuminuria. 178
Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials 176
In vivo oxidizability of LDL in type 2 diabetic patients in good and poor glycemic control 169
LIVER DAMAGE CAN BE ASSOCIATED WITH DEREGULATION OF THE DE NOVO LIPOGENESIS PATHWAY IN SUBJECTS WITH NON ALCOHOLIC FATTY LIVER DISEASE 167
Different Serum Free Fatty Acid Profiles in NAFLD Subjects and Healthy Controls after Oral Fat Load 165
Plasma Selenoprotein P levels are related to adipose tissue insulin resistance, composition of free fatty acids and liver fibrosis in non-diabetic patients with Non Alcoholic Fatty Liver Disease 160
The glucoregulatory and antilipolytic actions of insulin in abdominal obesity with normal or impaired glucose tolerance: an in vivo and in vitro study. 160
High-normal blood pressure and impaired renal function. A prospective study in a population-based cohort. 159
Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial 158
Contribution of visceral fat and hepatic fat to metabolic derangements and liver damage in NAFLD patients. 152
Serum glucose, insulin, C-peptide and plasma glucagon response to oral glucose after intravenous injection of different glucocorticoids at increasing doses in man 151
Influence of APOH protein polymorphism on apoH levels in normal and diabetic subjects. 150
Body fat is the main predictor of fibrinogen levels in healthy non-obese men 149
Rs12778366 single nucleotide polymorphism of Sirtuin 1 (SIRT1) and response to resveratrol supplementation in patients with type 2 diabetes mellitus. 149
Serum glucose, insulin and C-peptide response to oral glucose after intravenous administration of hydrocortisone and methylprednisolone in man 148
Impact of sirtuin-1 expression on H3K56 acetylation and oxidative stress: a double-blind randomized controlled trial with resveratrol supplementation 147
Increased hepatic glucose production and insulin resistance in subjects with non-alcoholic fatty liver disease is associated to increased plasma concentrations of glucogenic amino acids 145
Incidence of diabetes mellitus, cardiovascular outcomes and mortality after a 12-month lifestyle intervention: A 9-year follow-up 145
Characterization of the carbohydrate structures of apolipoprotein H through concanavalin A affinity chromatography. 142
Transcription factor 7-like 2 polymorphism modulates glucose and lipid homeostasis, adipokine profile, and hepatocyte apoptosis in NASH 142
TM6SF2 rs58542926 variant affects postprandial lipoprotein metabolism and glucose homeostasis in NAFLD. 142
Lipoprotein(a) in non-insulin-dependent diabetic patients with normo- and microalbuminuria 142
Relationships between human serum resistin, inflammatory markers and insulin resistance 141
Alteration in glucose metabolism after an oral glucose load in patients with non-alcoholic fatty liver disease. 139
Lipoprotein(a) and insulin treatment in non insulin dependent diabetic patients 136
Sterol Regulatory Element-Binding Factor 2 (SREBF-2) Predicts 7-Year NAFLD Incidence and Severity of Liver Disease and Lipoprotein and Glucose Dysmetabolism. 136
Lipoprotein(a) and insulin treatment in NIDDM patients 134
Feedback inhibition of insulin and glucagon secretion by insulin is altered in abdominal obesity with normal or impaired glucose tolerance. 133
The rs553668 polymorphism of ADRA2A gene predicts the worsening of fasting glucose values in a cohort of subjects without diabetes. A population-based study 133
Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C 132
Dietary habits and their relations to insulin sensitivity in non-alcoholic steatohepatitis. 132
Metabolic significance of hepatic steatosis in non alcoholic fatty liver disease and HCV chronic hepatitis 131
Abnormal insulin sensitivity in-chronic hepatitis C virus (HCV) infection: A link with steatosis? 131
Characterization and representative structures of N-oligosaccharides bound to apolipoprotein H. 131
Polymorphism in microsomal triglyceride transfer protein: a link between liver disease and atherogenic postprandial lipid profile in NASH? 130
The microbiota composition of the offspring of patients with gestational diabetes mellitus (GDM) 127
Increased liver expression of inflammatory mediators is associated with hepatic insulin resistance in lean, non-diabetic patients with chronic hepatitis C. 125
LIPIDOMICS REVEALS THAT LOW PLASMA UNSATURATED TO SATURATED FAT RATIOS ARE BIOMARKERS OF NAFLD AND LIVER DAMAGE 125
Subjects with non alcoholic fatty liver disease (NAFLD) display increased visceral and pancreatic fat associated with worse metabolic profile. 124
Alteration in glucose metabolism after an oral glucose load and relationship with liver damage in patients with NAFLD. 123
Age related changes of glucagon binding and activity in isolated rat hepatocytes. 121
Metabolic handling of an oral fat load in NAFLD patients. 120
Transcription factor 7-like 2 (TCF7L2) polymorphism and hyperglycemia in an adult Italian population-based cohort. 119
Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis. 119
Increased liver expression of inflammatory mediators is associated with hepatic insulin resistance in lean, non-diabetic CHC patients. 119
Impact of fat versus glucose load on oxidative stress in non-alcoholic fatty liver disease. 117
Effects of 6 months of resveratrol versus placebo on pentraxin 3 in patients with type 2 diabetes mellitus: a double-blind randomized controlled trial 117
Alteration in lipid metabolism after an oral fat load in subjects with NAFLD. 116
Type 1 autoimmune hepatitis and adipokines: new markers for activity and disease progression? 116
Effects of glucose and fat load on oxidative stress in patients with non-alcoholic fatty liver disease. 115
Validation of surrogate indexes of peripheral and hepatic insulin resistance and evaluation of their utility as non-invasive predictors of histological features in patients with Non-Alcoholic Fatty Liver Disease 114
Effects of resveratrol on bone health in type 2 diabetic patients. A double-blind randomized-controlled trial 114
Resistant hypertriglyceridemia in a patient with high plasma levels of apolipoprotein CII. 110
Apolipoprotein E polymorphism and stroke subtypes in an Italian cohort 110
Nel soggetto normale la ferritemia correla con l’HOMA. 110
The binding of apolipoprotein H (beta2-Glycoprotein I) to lipoproteins. 109
Is left ventricular hypertrophy a low-level inflammatory state? A population-based cohort study. 108
Non-alcoholic fatty liver disease from pathogenesis to management: an update. 106
Alteration in lipid metabolism after an oral fat load in non-alcoholic fatty liver disease. 106
Gut Microbiota as a Modulator of Cardiometabolic Risk: Mechanisms and Therapeutic Implications 105
Matabolomic analysis identifies new biomarkers of liver damage in NAFLD 105
Prevalence of undiagnosed metabolic syndrome in a population of adult asymptomatic subjects. 104
Acute myocardial infarction in young adults: prognostic role of angiotensin-converting enzyme, angiotensin II type I receptor, apolipoprotein E, endothelial constitutive nitric oxide synthase, and glycoprotein IIIa genetic polymorphisms at medium-term follow-up 104
Effetto della terapia steroidea sul controllo glicemico nel diabete insulino-trattato: confronto Deflazacort-Prednisone. 103
Oxidative stress-inducible factors promote liver fibrosis in patients with Non-Alcoholic Fatty Liver Disease. 102
Incidence of type 2 diabetes mellitus and glucose abnormalities in treated patients with chronic hepatitis C infection: Results of a controlled follow-up study. 101
DEREGULATION OF DE NOVO LIPOGENESIS CAN BE ASSOCIATED WITH LIVER DAMAGE IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE 101
Adiponectin gene polymorphism modulate acute adiponectin response to dietary fat: possible pathogenetic role in NASH 99
Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded? 99
Increased LDL-cholesterol susceptibility to oxidation contributes to oxidative damage in non alcoholic steatohepadtis (NASH). 99
Quantitative and qualitative analysis of plasma free fatty acids and their impact on liver damage in NAFLD patients. 99
Plasma Adiponectin Levels in Primary Biliary Cirrhosis: A Novel Perspective for Link Between Hypercholesterolemia and Protection Against Atherosclerosis 98
Apolipoprotein E allele frequencies in an Italian population: relation to age and lipid profile. 96
Noninvasive assessment of liver disease severity with liver fat score and CK-18 in NAFLD: Prognostic value of liver fat equation goes beyond hepatic fat estimation. 96
Serum free fatty acid composition is associated with different degrees of fibrosis. 96
Totale 21.625
Categoria #
all - tutte 82.464
article - articoli 0
book - libri 0
conference - conferenze 25.793
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 108.257


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20192.013 0 0 0 0 0 0 0 408 160 377 742 326
2019/20205.741 220 191 296 535 370 871 603 391 489 496 600 679
2020/20214.931 567 327 318 290 437 339 410 233 510 521 391 588
2021/20225.690 246 334 282 408 389 290 466 404 306 515 959 1.091
2022/20237.163 859 481 197 556 570 1.698 734 485 598 228 425 332
2023/20243.235 478 572 315 347 379 551 333 260 0 0 0 0
Totale 37.049